16 Channel Real Time Color Video Multiplexer

Toronto, Canada – GAO Tek Inc. (www.GAOTek.com) is offering its 16 channel real time color video multiplexer. It is designed to transfer recordings of signals from multiple security cameras into one output. This smart 16 channel real time color video multiplexer, model A0410001, features 50 fields/s in PAL mode and 60 fields/s in NTSC mode, an input of 16 loops BNC, 1.0 Vp-p 75 Ω and an output of 1 loop, 1.0 Vp-p75 Ω. For VCR, the input is BNC 1.0 Vp-p75 Ω/S-VHS and the output is BNC 1.0 Vp-p75 Ω/S-VHS. This video multiplexer handles several video signals at one time and splits a monitor into various display areas. It provides synchronous display and payback capability. The multiplexer includes such alarm modes as video loss alarm, video motion alarm and external alarm. The alarm duration is programmable from 2 to 999 seconds with 4 seconds default. It offers display modes including sequence switch, single picture, PiP, 4 pictures, 8 pictures, 9 pictures, 13 pictures, 16 pictures, freeze-frame and zoom. In addition, RS232/RS485 interfaces are provided for data transfer. This smart 16 channel real time color video multiplexer belongs to GAO’s family of Quad Processors & Video Multiplexers. Similar products in this line are 9 Channel Real Time Color Video Multiplexer which is widely used in security monitoring, highway monitoring, toll station video surveillance system, industrial closed circuit television surveillance and high quality video conferencing, 4 Channel Color Video Quad Processor and CCTV:Color Video Quad Processor. For sales inquiries please contact: 1-877 585-9555 ext. 601 – Toll Free (USA & Canada) 1-416 292-0038 ext. 601 – All Other Areas [email protected] About GAO Tek Inc. GAO Tek Inc. (www.GAOTek.com) specializes in researching, developing, manufacturing and selling top quality and cost effective telecom testers, electrical testers, embedded development tools, RFID readers and tags and other electronic measurement instruments.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.